<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603107</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-380-1878</org_study_id>
    <secondary_id>2015-004011-20</secondary_id>
    <nct_id>NCT02603107</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose&#xD;
      combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus&#xD;
      continuing on a regimen consisting of boosted atazanavir (ATV) or darunavir (DRV) plus either&#xD;
      emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) in&#xD;
      HIV-1 infected adults who are virologically suppressed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2015</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count at Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">578</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks, without regard to food.&#xD;
Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) for at least 48 weeks with food.&#xD;
Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>100 mg capsule coadministered orally with ATV or DRV once daily with food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV</intervention_name>
    <description>300 mg capsule administered orally once daily with food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV</intervention_name>
    <description>800 mg tablet administered orally once daily with food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COBI</intervention_name>
    <description>150 mg tablet coadministered orally with ATV or DRV once daily with food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
    <other_name>Tybost®</other_name>
    <other_name>GS-9350</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV/co</intervention_name>
    <description>300/150 mg FDC tablet administered orally once daily with food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
    <other_name>Evotaz®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV/co</intervention_name>
    <description>800/150 mg FDC tablet administered orally once daily with food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
    <other_name>Prezcobix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC/TDF</intervention_name>
    <description>200/300 mg FDC tablet administered orally once daily without regard to food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
    <other_name>Truvada®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC/3TC</intervention_name>
    <description>600/300 mg tablet administered orally once daily with or without regard to food</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>50/200/25 mg FDC tablet administered orally once daily without regard to food</description>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_label>Stay on Baseline Regimen (SBR)</arm_group_label>
    <other_name>Biktarvy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Currently receiving a once daily antiretroviral regimen consisting of ritonavir or&#xD;
             cobicistat boosted ATV or DRV plus either FTC/TDF or ABC/3TC for ≥ 6 months preceding&#xD;
             the screening visit&#xD;
&#xD;
          -  Adequate renal function:&#xD;
&#xD;
               -  Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83 mL/sec) according to the&#xD;
                  Cockcroft-Gault formula&#xD;
&#xD;
          -  Life expectancy ≥ 1 year&#xD;
&#xD;
          -  Currently on a stable regimen for ≥ 6 months preceding the screening visit with&#xD;
             documented plasma HIV-1 RNA &lt; 50 copies/mL for ≥ 6 months preceding the screening&#xD;
             visit (or undetectable HIV-1 RNA level according to the local assay being used if the&#xD;
             limit of detection is ≥ 50 copies/mL). Prior changes in antiretroviral regimen are&#xD;
             only allowed due to tolerability issues or for regimen simplification. Unconfirmed&#xD;
             virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or &quot;blip&quot;) prior&#xD;
             to screening are acceptable. (If the lower limit of detection of the local HIV-1 RNA&#xD;
             assay is &lt; 50 copies/mL [e.g., &lt; 20 copies/mL], the plasma HIV-1 RNA level cannot&#xD;
             exceed 50 copies/mL on two consecutive HIV-1 RNA tests)&#xD;
&#xD;
          -  Have no documented or suspected resistance to FTC, tenofovir, ABC or 3TC, including&#xD;
             but not limited to the reverse transcriptase resistance mutations K65R and M184V/I&#xD;
&#xD;
          -  No previous use of any approved or experimental integrase strand transfer inhibitor&#xD;
             (INSTI)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior&#xD;
             to screening&#xD;
&#xD;
          -  Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or&#xD;
             variceal bleeding)&#xD;
&#xD;
          -  Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3&#xD;
             months of study screening, or expected to receive these agents or systemic steroids&#xD;
             during the study (eg, corticosteroids, immunoglobulins, and other immune- or cytokine&#xD;
             based therapies)&#xD;
&#xD;
          -  Current alcohol or substance use judged by the Investigator to potentially interfere&#xD;
             with subject study compliance&#xD;
&#xD;
          -  A history of or ongoing malignancy (including untreated carcinoma in-situ) other than&#xD;
             cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive&#xD;
             cutaneous squamous carcinoma. Individuals with biopsy-confirmed cutaneous KS are&#xD;
             eligible, but must not have received any systemic therapy for KS within 30 days of Day&#xD;
             1 and are not anticipated to require systemic therapy during the study&#xD;
&#xD;
          -  Active, serious infections (other than HIV 1 infection) requiring parenteral&#xD;
             antibiotic or antifungal therapy within 30 days prior to Day 1&#xD;
&#xD;
          -  Participation in any other clinical trial, including observational studies, without&#xD;
             prior approval from the sponsor is prohibited while participating in this trial&#xD;
&#xD;
          -  Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             Investigator, would make the individual unsuitable for the study or unable to comply&#xD;
             with the dosing requirements&#xD;
&#xD;
          -  Any known allergies to the excipients of B/F/TAF FDC or ATV, RTV, DRV, COBI, FTC/TDF&#xD;
             or ABC/3TC&#xD;
&#xD;
          -  Females who are pregnant (as confirmed by positive serum pregnancy test)&#xD;
&#xD;
          -  Females who are breastfeeding&#xD;
&#xD;
          -  Acute hepatitis in the 30 days prior to study entry&#xD;
&#xD;
          -  Chronic hepatitis B infection in individuals not on a TDF containing regimen, as&#xD;
             determined by either:&#xD;
&#xD;
               -  Positive hepatitis B virus (HBV) surface antigen and negative HBV surface&#xD;
                  antibody, regardless of HBV core antibody status, at the screening visit&#xD;
&#xD;
               -  Positive HBV core antibody and negative HBV surface antibody, regardless of HBV&#xD;
                  surface antigen status, at the screening visit&#xD;
&#xD;
          -  Active tuberculosis infection&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803-1851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilton Manors</city>
        <state>Florida</state>
        <zip>33305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>01211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>1105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003-7313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3068</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3141</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <zip>00731</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio Piedras</city>
        <zip>935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B4 6DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <zip>BN2 3EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW10 9TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M13 0FH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Dominican Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18.</citation>
    <PMID>29925490</PMID>
  </results_reference>
  <results_reference>
    <citation>Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347. Erratum in: J Antimicrob Chemother. 2019 Dec 1;74(12):3646-3647.</citation>
    <PMID>31430369</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2015</study_first_posted>
  <results_first_submitted>May 3, 2018</results_first_submitted>
  <results_first_submitted_qc>May 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2018</results_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cobicistat mixture with darunavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>18 months after study completion</ipd_time_frame>
    <ipd_access_criteria>A secured external environment with username, password, and RSA code.</ipd_access_criteria>
    <ipd_url>https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol: Original</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02603107/Prot_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 1</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02603107/Prot_005.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: Amendment 2</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02603107/Prot_006.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Week 48</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02603107/SAP_008.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Final</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02603107/SAP_009.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in Dominican Republic, North America, Australia, and Europe. The first participant was screened on 20 November 2015. The last study visit occurred on 23 December 2019.</recruitment_details>
      <pre_assignment_details>707 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>B/F/TAF</title>
          <description>Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed-dose combination (FDC) tablet orally once daily for at least 48 weeks, without regard to food.&#xD;
Extension Phase: After Week 48, participants in countries where B/F/TAF was not available were given the option to receive B/F/TAF for up to 96 additional weeks or until the product became accessible to participants through an access program, or until Gilead Sciences elected to discontinue the study in that country, whichever occurred first.</description>
        </group>
        <group group_id="P2">
          <title>Stay on Baseline Regimen (SBR)</title>
          <description>Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg) FDC tablet or abacavir/lamivudine (ABC/3TC) (600/300 mg) FDC tablet administered orally once daily for at least 48 weeks with food.&#xD;
Extension Phase: After Week 48, participants in countries where B/F/TAF was not available were given the option to receive B/F/TAF for up to 96 additional weeks or until the product became accessible to participants through an access program, or until Gilead Sciences elected to discontinue the study in that country, whichever occurred first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Optional Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="272">3 participants who completed the Randomized Phase did not continue in the Optional Extension Phase.</participants>
                <participants group_id="P2" count="245">21 participants who completed the Randomized Phase did not continue in the Optional Extension Phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's discretion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated in extension phase</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: all randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>B/F/TAF</title>
          <description>Randomized Phase: B/F/TAF (50/200/25 mg) FDC tablet administered orally once daily for at least 48 weeks without regard to food.&#xD;
Extension Phase: After Week 48, participants in countries where B/F/TAF was not available were given the option to receive B/F/TAF for up to 96 additional weeks or until the product became accessible to participants through an access program, or until Gilead Sciences elected to discontinue the study in that country, whichever occurred first.</description>
        </group>
        <group group_id="B2">
          <title>Stay on Baseline Regimen (SBR)</title>
          <description>Randomized Phase: Participants remained on current ARV regimen consisting of RTV or COBI boosted ATV or DRV, plus either FTC/TDF (200/300 mg) FDC tablets or ABC/3TC (600/300 mg) FDC tablet administered orally once daily for at least 48 weeks with food.&#xD;
Extension Phase: After Week 48, participants in countries where B/F/TAF was not available were given the option to receive B/F/TAF for up to 96 additional weeks or until the product became accessible to participants through an access program, or until Gilead Sciences elected to discontinue the study in that country, whichever occurred first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="290"/>
            <count group_id="B2" value="287"/>
            <count group_id="B3" value="577"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="10.5"/>
                    <measurement group_id="B2" value="46" spread="10.5"/>
                    <measurement group_id="B3" value="46" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="240"/>
                    <measurement group_id="B3" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominican Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA Category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 50 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="277"/>
                    <measurement group_id="B3" value="562"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Cell Count</title>
          <units>cells/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="669" spread="303.4"/>
                    <measurement group_id="B2" value="657" spread="285.0"/>
                    <measurement group_id="B3" value="663" spread="294.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Cell Count Category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 50 cells/μL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 to &lt; 200 cells/μL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 200 to &lt; 350 cells/μL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 350 to &lt; 500 cells/μL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 500 cells/μL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV Disease Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asymptomatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Symptomatic HIV Infection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acquired Immunodeficiency Syndrome (AIDS)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior ARV Regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Boosted ATV + ABC/3TC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Boosted DRV + ABC/3TC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Boosted ATV + FTC/TDF</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Boosted DRV + FTC/TDF</title>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm</title>
        <description>The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set: all participants who were randomized into the study and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Randomized Phase: B/F/TAF (50/200/25 mg) FDC tablet administered orally once daily for at least 48 weeks without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Randomized Phase: Participants remained on current ARV regimen consisting of RTV or COBI boosted ATV or DRV, plus either FTC/TDF (200/300 mg) FDC tablet or ABC/3TC (600/300 mg) FDC tablet administered orally once daily for at least 48 weeks with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm</title>
          <description>The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Full Analysis Set: all participants who were randomized into the study and received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 in the B/F/TAF group was at least 4% higher than the rate in the SBR group; the alternative hypothesis was that the percentage of participants with HIV-1 RNA ≥ 50 copies/mL in the B/F/TAF group was less than 4% higher than that in the SBR group.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 520 participants (260 participants per treatment group) would provide at least 90% power to establish a non-inferiority margin of 4% in the Week 48 response rate (HIV-1 RNA ≥ 50 copies/mL) between the 2 treatment groups. Sample size was based on the assumptions that both treatment groups have 2% of participants with HIV-1 RNA ≥ 50 copies/mL (based on Gilead Genvoya and Stribild studies) and that the significance level of the test is at a 1-sided 0.025 level.</non_inferiority_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95.002</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>The difference in percentages and its 95.002% confidence interval (CI) were calculated based on an unconditional exact method using 2 inverted 1-sided tests.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm</title>
        <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Randomized Phase: B/F/TAF (50/200/25 mg) FDC tablet administered orally once daily for at least 48 weeks without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Randomized Phase: Participants remained on current ARV regimen consisting of RTV or COBI boosted ATV or DRV, plus either FTC/TDF (200/300 mg) FDC tablet or ABC/3TC (600/300 mg) FDC tablet administered orally once daily for at least 48 weeks with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm</title>
          <description>The percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority of B/F/TAF would be established if the lower bound of the 2-sided 95.002% CI of the difference between the treatment groups (B/F/TAF group - SBR group) in the percentage of participants with HIV-1 RNA &lt; 50 copies/mL is greater than -10%.</non_inferiority_desc>
            <param_type>Difference in Percentages</param_type>
            <param_value>3.2</param_value>
            <ci_percent>95.002</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
            <estimate_desc>The difference in percentages and its 95.002% confidence interval (CI) were calculated based on an unconditional exact method using 2 inverted 1-sided tests.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count at Week 48</title>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Participants in the Full Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Randomized Phase: B/F/TAF (50/200/25 mg) FDC tablet administered orally once daily for at least 48 weeks without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Randomized Phase: Participants remained on current ARV regimen consisting of RTV or COBI boosted ATV or DRV, plus either FTC/TDF (200/300 mg) FDC tablet or ABC/3TC (600/300 mg) FDC tablet administered orally once daily for at least 48 weeks with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count at Week 48</title>
          <population>Participants in the Full Analysis Set with available data were analyzed.</population>
          <units>cells/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="151.2"/>
                    <measurement group_id="O2" value="0" spread="159.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.068</p_value>
            <method>ANOVA</method>
            <param_type>Difference in Least Squares Means (LSM)</param_type>
            <param_value>25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose date up to last dose date (maximum: 181 weeks) plus 30 days</time_frame>
      <desc>Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>B/F/TAF (Randomized Phase)</title>
          <description>Randomized Phase: B/F/TAF (50/200/25 mg) FDC tablet administered orally once daily for at least 48 weeks without regard to food.</description>
        </group>
        <group group_id="E2">
          <title>Stay on Baseline Regimen (SBR) (Randomized Phase)</title>
          <description>Randomized Phase: Participants remained on current ARV regimen consisting of RTV or COBI boosted ATV or DRV, plus either FTC/TDF (200/300 mg) FDC tablet or ABC/3TC (600/300 mg) FDC tablet administered orally once daily for at least 48 weeks with food.</description>
        </group>
        <group group_id="E3">
          <title>Extension B/F/TAF From B/F/TAF</title>
          <description>After Week 48, participants in countries where B/F/TAF was not available were given the option to receive B/F/TAF for up to 96 additional weeks or until the product became accessible to participants through an access program, or until Gilead Sciences elected to discontinue the study in that country, whichever occurred first.</description>
        </group>
        <group group_id="E4">
          <title>Extension B/F/TAF From SBR</title>
          <description>After Week 48, participants in countries where B/F/TAF was not available were given the option to receive B/F/TAF for up to 96 additional weeks or until the product became accessible to participants through an access program, or until Gilead Sciences elected to discontinue the study in that country, whichever occurred first.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myxomatous mitral valve degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stoma site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="113" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="287"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

